Latest Regulatory Developments News

Pantera Lithium Limited has agreed to sell its Smackover Lithium Project subsidiary to Energy Exploration Technologies Inc. for A$40 million, significantly strengthening its financial position and strategic exposure to U.S. lithium assets.

Peak Rare Earths Limited has updated its acquisition scheme, replacing Ganzhou Chenguang with Shenghe Resources (Singapore) Pte. Ltd. as the acquiring party, simplifying regulatory hurdles and valuing the company at nearly A$158 million.

Centex Limited and Agriflex Pty Ltd, currently under voluntary administration, have received a Deed of Company Arrangement proposal from PRL Global Limited involving an $8.2 million contribution and a share transfer. Administrators recommend creditors approve the DOCA for better returns and operational continuity.

Macquarie Group Limited reported a 5% increase in FY25 profit to A$3.715 billion, declaring a higher dividend and announcing a key CFO transition. The group also outlined a strategic divestment and cautious outlook for FY26.

Macquarie Group reported a decline in net profit contribution for the first quarter of FY26, driven by mixed performances across its divisions, while maintaining a robust capital surplus and announcing a key CFO transition.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Woodside Energy reported a 2% rise in quarterly production and lowered unit costs, while the Louisiana LNG Project’s final investment decision and a major Stonepeak partnership unlock significant future value.

Coast Entertainment Holdings reports a robust FY25 with double-digit growth in visitation and revenue, driven by new attractions and strong promotional campaigns. Despite weather disruptions and cautious international recovery, the company starts FY26 on a high note.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

The Takeovers Panel has declined to intervene in the ongoing control tussle for New World Resources, despite concerns over delayed disclosure and contested share acquisitions.

Omni Bridgeway confirms the US Budget Bill signed on 4 July 2025 excludes the proposed Legal Finance tax, a move welcomed by the company amid broad political support.

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.